What happened
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) set terms for an underwritten public offering of 11,538,462 common shares at $13.00 apiece. The financing would add cash to the cancer drug developer and dilute shareholders who do not buy any of the new stock.
SELLAS expects the base sale to generate $150 million before underwriting discounts, commissions and offering expenses. The company is issuing all the stock in the deal, so the proceeds would go to SELLAS rather than to selling shareholders.
Why it matters
The underwriters can expand the sale beyond the base deal. They have a 30-day option to buy up to 1,730,769 additional shares at the public offering price, less underwriting discounts and commissions. Full exercise would increase the number of shares sold by 15.0% over the base offering priced on Nov. 18, OptimistFi calculates.
The larger share count is built into the company’s estimate of net proceeds. SELLAS expects about $161.8 million after underwriting discounts, commissions and estimated offering expenses if the underwriters exercise the option in full. The option therefore gives the underwriters control over whether SELLAS sells additional common shares on those terms.
The business behind the financing is still developing cancer treatments. Its lead candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in multiple tumor types. SELLAS is also developing SLS009, known as tambiciclib, for patients with acute myeloid leukemia and unfavorable prognostic factors.
OptimistFi views the deal as mixed because it trades a larger share count for more cash to pursue clinical and regulatory progress. The payoff for holders still depends on whether the drug programs produce evidence strong enough to support a partnership or a commercial launch.
What's next
SELLAS expects the offering to close on or about Nov. 20 if customary conditions are met. Closing would secure the base financing, while any additional proceeds would depend on the underwriters exercising their option.

